Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZD6126 + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ZD6126 + oxaliplatin + 5-fluorouracil + leucovorin is a multi-agent combination chemotherapy regimen investigated primarily for cancer treatment. **ZD6126** is a vascular-targeting agent (a prodrug of N-acetylcolchinol) that disrupts tumor blood vessels and induces tumor necrosis. **Oxaliplatin** is a third-generation platinum compound that crosslinks DNA, causing inhibition of DNA replication and transcription, leading to cellular apoptosis. **5-fluorouracil** is an antimetabolite that inhibits thymidylate synthase, suppressing DNA synthesis and function. **Leucovorin** (folinic acid) is not cytotoxic alone but enhances the binding of 5-fluorouracil to thymidylate synthase, increasing its efficacy. This combination was studied for advanced cancers, notably colorectal cancer, to evaluate improvements in efficacy and tolerability and includes an investigational antiangiogenic mechanism with ZD6126 alongside DNA-damaging platinum and antimetabolite chemotherapies[4][2][1].
- Other names
- ZD6126 plus oxaliplatin, 5-fluorouracil, and leucovorin
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on ZD6126 + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZD6126 + oxaliplatin + 5-fluorouracil + leucovorin.